Value Will Pave The Way For Innovative Brands, Pfizer’s Germano Says
Executive Summary
Global Innovative Pharma Business President Geno Germano sat down with “The Pink Sheet” to discuss growth strategy, M&A and Pfizer’s increasing focus on value in a changing health care world.
You may also be interested in...
Pfizer Gets Palbociclib To NDA Finish Line On Phase II Data
Pfizer finished a rolling NDA for the high-profile breast cancer drug, the first-in-class CDK-4/6 inhibitor. Whether or not FDA will agree Phase II data results from the PALOMA-1 trial are sufficient to grant accelerated approval remains to be seen.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.